Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 81

1.

Allergic Reactions and Cross-Reactivity Potential with Beta-Lactamase Inhibitors.

Stover KR, Barber KE, Wagner JL.

Pharmacy (Basel). 2019 Jun 28;7(3). pii: E77. doi: 10.3390/pharmacy7030077. Review.

2.

Impact of Obesity on Acyclovir-Induced Nephrotoxicity.

Barber KE, Wagner JL, Stover KR.

Open Forum Infect Dis. 2019 Mar 7;6(4):ofz121. doi: 10.1093/ofid/ofz121. eCollection 2019 Apr.

3.

Effect of fish oil supplement administration method on tolerability and adherence: a randomized pilot clinical trial.

Malinowski SS, Barber KE, Kishk OA, Mays AA, Jones SR, Turner AL, Riche DM.

Pilot Feasibility Stud. 2019 Jan 8;5:3. doi: 10.1186/s40814-018-0387-0. eCollection 2019.

4.

Impact of an infectious diseases advanced pharmacy practice experience on student knowledge.

Stover KR, King ST, Barber KE.

Curr Pharm Teach Learn. 2018 Aug;10(8):1022-1025. doi: 10.1016/j.cptl.2018.05.002. Epub 2018 Jun 11.

PMID:
30314536
5.

Omadacycline Enters the Ring: A New Antimicrobial Contender.

Barber KE, Bell AM, Wingler MJB, Wagner JL, Stover KR.

Pharmacotherapy. 2018 Dec;38(12):1194-1204. doi: 10.1002/phar.2185. Epub 2018 Nov 15. Erratum in: Pharmacotherapy. 2019 Feb;39(2):207.

6.

Newest lipoglycopeptides for the management of acute bacterial skin and skin structure infections.

Bell AM, King ST, Barber KE, Adcock KG, Wagner JL, Stover KR.

Nurse Pract. 2018 Oct;43(10):31-37. doi: 10.1097/01.NPR.0000544995.21102.7f.

PMID:
30153191
7.

Ceftazidime/avibactam versus standard-of-care agents against carbapenem-resistant Enterobacteriaceae harbouring blaKPC in a one-compartment pharmacokinetic/pharmacodynamic model.

Barber KE, Pogue JM, Warnock HD, Bonomo RA, Kaye KS.

J Antimicrob Chemother. 2018 Sep 1;73(9):2405-2410. doi: 10.1093/jac/dky213.

PMID:
29939267
8.

Risk Factors for Failure in Complicated Intraabdominal Infections.

White BP, Wagner JL, Barber KE, King ST, Stover KR.

South Med J. 2018 Feb;111(2):125-132. doi: 10.14423/SMJ.0000000000000770.

PMID:
29394432
9.

Impact of an antifungal stewardship intervention on optimization of candidemia management.

Rac H, Wagner JL, King ST, Barber KE, Stover KR.

Ther Adv Infect Dis. 2018 Jan;5(1):3-10. doi: 10.1177/2049936117745267. Epub 2017 Dec 10.

10.

Ceftriaxone for the Treatment of Methicillin-susceptible Staphylococcus aureus Bacteremia: A Case Series.

Lowe RA, Barber KE, Wagner JL, Bell-Harlan AM, Stover KR.

J Pharmacol Pharmacother. 2017 Jul-Sep;8(3):140-144. doi: 10.4103/jpp.JPP_5_17.

11.

Time-Kill Analysis of Ceftolozane/Tazobactam Efficacy Against Mucoid Pseudomonas aeruginosa Strains from Cystic Fibrosis Patients.

Rac H, Stover KR, Wagner JL, King ST, Warnock HD, Barber KE.

Infect Dis Ther. 2017 Dec;6(4):507-513. doi: 10.1007/s40121-017-0176-8. Epub 2017 Oct 20.

12.

Shifts in antimicrobial consumption and infection rates before and during a piperacillin/tazobactam shortage.

King ST, Barber KE, Parham JJ, Stover KR.

J Glob Antimicrob Resist. 2017 Dec;11:111-113. doi: 10.1016/j.jgar.2017.07.015. Epub 2017 Jul 31.

PMID:
28774865
13.

Dalbavancin Use for the Treatment of Methicillin-resistant Staphylococcus aureus Pneumonia.

Barber KE, Tirmizi A, Finley R, Stover KR.

J Pharmacol Pharmacother. 2017 Apr-Jun;8(2):77-79. doi: 10.4103/jpp.JPP_2_17.

14.

Mechanisms of fosfomycin resistance in carbapenem-resistant Enterobacter sp.

White BP, Stover KR, Barber KE, Galloway RC, Sullivan DC, King ST.

Int J Antimicrob Agents. 2017 Nov;50(5):690-692. doi: 10.1016/j.ijantimicag.2017.05.010. Epub 2017 Jul 5.

PMID:
28688955
15.

Managing acute bacterial skin and skin structure infections: Focus on new lipoglycopeptides.

Bell AM, King ST, Barber KE, Adcock KG, Wagner JL, Stover KR.

Nurse Pract. 2017 May 12;42(5):1-6. doi: 10.1097/01.NPR.0000515428.68779.87.

PMID:
28406838
16.

Successful Treatment of Necrotizing Fasciitis and Streptococcal Toxic Shock Syndrome with the Addition of Linezolid.

Rac H, Bojikian KD, Lucar J, Barber KE.

Case Rep Infect Dis. 2017;2017:5720708. doi: 10.1155/2017/5720708. Epub 2017 Feb 19.

17.

Ceftaroline for the treatment of methicillin-resistant Staphylococcus aureus bacteremia.

White BP, Barber KE, Stover KR.

Am J Health Syst Pharm. 2017 Feb 15;74(4):201-208. doi: 10.2146/ajhp160006. Review.

PMID:
28179245
18.

Ceftazidime/Avibactam: Who Says You Can't Teach an Old Drug New Tricks?

Barber KE, Ortwine JK, Akins RL.

J Pharm Pharm Sci. 2016 Oct - Dec;19(4):448-464. doi: 10.18433/J3X31R. Review.

19.

Comparison of susceptibility patterns using commercially available susceptibility testing methods performed on prevalent Candida spp.

Cretella D, Barber KE, King ST, Stover KR.

J Med Microbiol. 2016 Dec;65(12):1445-1451. doi: 10.1099/jmm.0.000383. Epub 2016 Nov 1.

PMID:
27902377
20.

Intravenous Vancomycin Dosing in the Elderly: A Focus on Clinical Issues and Practical Application.

Barber KE, Bell AM, Stover KR, Wagner JL.

Drugs Aging. 2016 Dec;33(12):845-854. Review.

21.

Pronounced heterogeneity observed in high-level daptomycin-resistant viridans group streptococci.

Akins RL, Barber KE, Palmer KL.

J Glob Antimicrob Resist. 2016 Dec;7:159-166. doi: 10.1016/j.jgar.2016.09.005. Epub 2016 Oct 29.

PMID:
27835845
22.

Impact of piperacillin-tazobactam shortage on meropenem use: implications for antimicrobial stewardship programs.

Barber KE, Bell AM, Travis King S, Parham JJ, Stover KR.

Braz J Infect Dis. 2016 Nov - Dec;20(6):631-634. doi: 10.1016/j.bjid.2016.08.001. Epub 2016 Sep 5.

23.
24.

Elbasvir/Grazoprevir: A Review of the Latest Agent in the Fight against Hepatitis C.

Bell AM, Wagner JL, Barber KE, Stover KR.

Int J Hepatol. 2016;2016:3852126. doi: 10.1155/2016/3852126. Epub 2016 Jun 15. Review.

25.

Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.

Smith JR, Arya A, Yim J, Barber KE, Hallesy J, Singh NB, Rybak MJ.

Antimicrob Agents Chemother. 2016 Jun 20;60(7):3970-5. doi: 10.1128/AAC.01666-15. Print 2016 Jul.

26.

Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.

Barber KE, Smith JR, Raut A, Rybak MJ.

J Antimicrob Chemother. 2016 Jan;71(1):152-5. doi: 10.1093/jac/dkv302. Epub 2015 Oct 16.

PMID:
26476277
28.
29.

β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.

Smith JR, Barber KE, Raut A, Rybak MJ.

Antimicrob Agents Chemother. 2015 May;59(5):2842-8. doi: 10.1128/AAC.00053-15. Epub 2015 Mar 9.

30.

Therapeutic options for vancomycin-resistant enterococcal bacteremia.

Barber KE, King ST, Stover KR, Pogue JM.

Expert Rev Anti Infect Ther. 2015 Mar;13(3):363-77. doi: 10.1586/14787210.2015.1001839. Review.

PMID:
25661903
31.

β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.

Smith JR, Barber KE, Raut A, Aboutaleb M, Sakoulas G, Rybak MJ.

J Antimicrob Chemother. 2015;70(6):1738-43. doi: 10.1093/jac/dkv007. Epub 2015 Feb 1.

32.

Comment on: Failure of combination therapy with daptomycin and synergistic ceftriaxone for enterococcal endocarditis.

Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ.

J Antimicrob Chemother. 2015 Apr;70(4):1272-3. doi: 10.1093/jac/dku480. Epub 2014 Nov 27. No abstract available.

PMID:
25433012
33.

Ceftobiprole and ampicillin increase daptomycin susceptibility of daptomycin-susceptible and -resistant VRE.

Werth BJ, Barber KE, Tran KN, Nonejuie P, Sakoulas G, Pogliano J, Rybak MJ.

J Antimicrob Chemother. 2015 Feb;70(2):489-93. doi: 10.1093/jac/dku386. Epub 2014 Oct 9.

PMID:
25304643
34.

The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.

Barber KE, Werth BJ, Rybak MJ.

J Antimicrob Chemother. 2015 Feb;70(2):505-9. doi: 10.1093/jac/dku378. Epub 2014 Sep 22.

35.

High-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.

Smith JR, Claeys KC, Barber KE, Rybak MJ.

Curr Infect Dis Rep. 2014 Oct;16(10):429. doi: 10.1007/s11908-014-0429-6.

36.

Observation of "seesaw effect" with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains.

Barber KE, Ireland CE, Bukavyn N, Rybak MJ.

Infect Dis Ther. 2014 Jun;3(1):35-43. doi: 10.1007/s40121-014-0023-0. Epub 2014 Jan 18.

37.

Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia.

Barber KE, Rybak MJ, Sakoulas G.

J Antimicrob Chemother. 2015 Jan;70(1):311-3. doi: 10.1093/jac/dku322. Epub 2014 Aug 13. No abstract available.

PMID:
25125677
38.

Potent synergy of ceftobiprole plus daptomycin against multiple strains of Staphylococcus aureus with various resistance phenotypes.

Barber KE, Werth BJ, Ireland CE, Stone NE, Nonejuie P, Sakoulas G, Pogliano J, Rybak MJ.

J Antimicrob Chemother. 2014 Nov;69(11):3006-10. doi: 10.1093/jac/dku236. Epub 2014 Jul 1.

PMID:
24990867
39.

Evaluation of the novel combination of daptomycin plus ceftriaxone against vancomycin-resistant enterococci in an in vitro pharmacokinetic/pharmacodynamic simulated endocardial vegetation model.

Hall Snyder A, Werth BJ, Barber KE, Sakoulas G, Rybak MJ.

J Antimicrob Chemother. 2014 Aug;69(8):2148-54. doi: 10.1093/jac/dku113. Epub 2014 Apr 28.

PMID:
24777900
41.

A novel approach utilizing biofilm time-kill curves to assess the bactericidal activity of ceftaroline combinations against biofilm-producing methicillin-resistant Staphylococcus aureus.

Barber KE, Werth BJ, McRoberts JP, Rybak MJ.

Antimicrob Agents Chemother. 2014 May;58(5):2989-92. doi: 10.1128/AAC.02764-13. Epub 2014 Mar 10.

42.

Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy.

Casapao AM, Davis SL, Barr VO, Klinker KP, Goff DA, Barber KE, Kaye KS, Mynatt RP, Molloy LM, Pogue JM, Rybak MJ.

Antimicrob Agents Chemother. 2014 May;58(5):2541-6. doi: 10.1128/AAC.02371-13. Epub 2014 Feb 18.

43.

Current and prospective treatments for multidrug-resistant gram-positive infections.

Rybak JM, Barber KE, Rybak MJ.

Expert Opin Pharmacother. 2013 Oct;14(14):1919-32. doi: 10.1517/14656566.2013.820276. Epub 2013 Jul 22. Review.

PMID:
23876168
44.

Carbapenem-resistant Acinetobacter baumannii: epidemiology, surveillance and management.

Pogue JM, Mann T, Barber KE, Kaye KS.

Expert Rev Anti Infect Ther. 2013 Apr;11(4):383-93. doi: 10.1586/eri.13.14. Review.

PMID:
23566148
45.

Abnormalities of the der(12)t(12;21) in ETV6-RUNX1 acute lymphoblastic leukemia.

Al-Shehhi H, Konn ZJ, Schwab CJ, Erhorn A, Barber KE, Wright SL, Gabriel AS, Harrison CJ, Moorman AV.

Genes Chromosomes Cancer. 2013 Feb;52(2):202-13. doi: 10.1002/gcc.22021. Epub 2012 Oct 18.

PMID:
23077088
46.

Fluorescence In situ hybridization (FISH) as a tool for the detection of significant chromosomal abnormalities in childhood leukaemia.

Konn ZJ, Wright SL, Barber KE, Harrison CJ.

Methods Mol Biol. 2009;538:29-55. doi: 10.1007/978-1-59745-418-6_3.

PMID:
19277578
47.

A comprehensive analysis of the CDKN2A gene in childhood acute lymphoblastic leukemia reveals genomic deletion, copy number neutral loss of heterozygosity, and association with specific cytogenetic subgroups.

Sulong S, Moorman AV, Irving JA, Strefford JC, Konn ZJ, Case MC, Minto L, Barber KE, Parker H, Wright SL, Stewart AR, Bailey S, Bown NP, Hall AG, Harrison CJ.

Blood. 2009 Jan 1;113(1):100-7. doi: 10.1182/blood-2008-07-166801. Epub 2008 Oct 6.

48.

Molecular cytogenetic characterization of TCF3 (E2A)/19p13.3 rearrangements in B-cell precursor acute lymphoblastic leukemia.

Barber KE, Harrison CJ, Broadfield ZJ, Stewart AR, Wright SL, Martineau M, Strefford JC, Moorman AV.

Genes Chromosomes Cancer. 2007 May;46(5):478-86.

PMID:
17311319
49.

Interphase molecular cytogenetic screening for chromosomal abnormalities of prognostic significance in childhood acute lymphoblastic leukaemia: a UK Cancer Cytogenetics Group Study.

Harrison CJ, Moorman AV, Barber KE, Broadfield ZJ, Cheung KL, Harris RL, Jalali GR, Robinson HM, Strefford JC, Stewart A, Wright S, Griffiths M, Ross FM, Harewood L, Martineau M.

Br J Haematol. 2005 May;129(4):520-30.

PMID:
15877734
50.

Derivative chromosome 9 deletions are a significant feature of childhood Philadelphia chromosome positive acute lymphoblastic leukaemia.

Robinson HM, Martineau M, Harris RL, Barber KE, Jalali GR, Moorman AV, Strefford JC, Broadfield ZJ, Cheung KL, Harrison CJ.

Leukemia. 2005 Apr;19(4):564-71.

PMID:
15716990

Supplemental Content

Loading ...
Support Center